Sage Therapeutics Announces Topline Results from Phase 2 DIMENSION StudyCAMBRIDGE, Mass. – November 20, 2024 – Sage Therapeutics, Inc. (Nasdaq: SAGE) recently disclosed the topline results from its Phase 2 DIMENSION Study, evaluating the efficacy of

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Sage Therapeutics’s 8K filing here.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.